Leaders in Neuroblastoma Research

Our physicians are leading clinical trials testing new treatments to improve outcomes in children with newly diagnosed high-risk and non-high-risk neuroblastoma. We are also leading clinical trials for children with relapsed neuroblastoma or tumors that have not responded to conventional treatments and clinical studies investigating late effects in high-risk neuroblastoma survivors.


In addition, physicians and scientists are collaborating to:

  • Develop new biomarkers of treatment response and survival that have the potential to transform treatment approaches
  • Identify new therapeutic targets and investigate the biological underpinnings that drive aggressive neuroblastoma growth

Ongoing Neuroblastoma Research Studies

Susan Cohn, MD, serves as co-chair of the International Neuroblastoma Risk Group (INRG) task force, a group of pediatric oncologists dedicated to transforming neuroblastoma research and clinical care. In collaboration with Samuel Volchenboum, MD, PhD, MS, the INRG task force developed the Pediatric Cancer Data Commons (PCDC), a platform that harnesses clinical data from patients with other types of pediatric cancers from around the globe, enabling new, cross-disease research studies.